Lim SW - Search Results

1

Personalized medicine and pharmacogenetic biomarkers: progress in molecular oncology testing.

Ong FS, Das K, Wang J, Vakil H, Kuo JZ, Blackwell WL, Lim SW, Goodarzi MO, Bernstein KE, Rotter JI, Grody WW. Ong FS, et al. Among authors: lim sw. Expert Rev Mol Diagn. 2012 Jul;12(6):593-602. doi: 10.1586/erm.12.59. Expert Rev Mol Diagn. 2012. PMID: 22845480 Free PMC article. Review.

2

Temozolomide: a novel treatment for pituitary carcinoma.

Lim S, Shahinian H, Maya MM, Yong W, Heaney AP. Lim S, et al. Lancet Oncol. 2006 Jun;7(6):518-20. doi: 10.1016/S1470-2045(06)70728-8. Lancet Oncol. 2006. PMID: 16750503 No abstract available.

3

Prolactinoma ErbB receptor expression and targeted therapy for aggressive tumors.

Cooper O, Mamelak A, Bannykh S, Carmichael J, Bonert V, Lim S, Cook-Wiens G, Ben-Shlomo A. Cooper O, et al. Endocrine. 2014 Jun;46(2):318-27. doi: 10.1007/s12020-013-0093-x. Epub 2013 Nov 28. Endocrine. 2014. PMID: 24287797 Free PMC article. Clinical Trial.

4

Multimodal approach to anaplastic thyroid cancer.

Burnison CM, Lim S. Burnison CM, et al. Oncology (Williston Park). 2012 Apr;26(4):378-84, 390-8. Oncology (Williston Park). 2012. PMID: 22655531 Free article. Review.

5

A Phase I Study of Ruxolitinib, Lenalidomide, and Steroids for Patients with Relapsed/Refractory Multiple Myeloma.

Berenson JR, To J, Spektor TM, Martinez D, Turner C, Sanchez A, Ghermezi M, Eades BM, Swift RA, Schwartz G, Eshaghian S, Stampleman L, Moss RA, Lim S, Vescio R. Berenson JR, et al. Clin Cancer Res. 2020 May 15;26(10):2346-2353. doi: 10.1158/1078-0432.CCR-19-1899. Epub 2020 Jan 14. Clin Cancer Res. 2020. PMID: 31937615 Clinical Trial.

6

A phase 2 trial of the efficacy and safety of elotuzumab in combination with pomalidomide, carfilzomib and dexamethasone for high-risk relapsed/refractory multiple myeloma.

Yashar D, Spektor TM, Martinez D, Ghermezi M, Swift RA, Eades B, Schwartz G, Eshaghian S, Lim S, Vescio R, Berenson JR. Yashar D, et al. Leuk Lymphoma. 2022 Apr;63(4):975-983. doi: 10.1080/10428194.2021.2005044. Epub 2021 Nov 24. Leuk Lymphoma. 2022. PMID: 34818965 Clinical Trial.

7

Rituximab as successful therapy in a patient with refractory paroxysmal cold hemoglobinuria.

Koppel A, Lim S, Osby M, Garratty G, Goldfinger D. Koppel A, et al. Transfusion. 2007 Oct;47(10):1902-4. doi: 10.1111/j.1537-2995.2007.01414.x. Transfusion. 2007. PMID: 17880618

8

Alopecia areata as a paraneoplastic syndrome of Hodgkin's lymphoma: A case report.

Gong J, Lim SW. Gong J, et al. Among authors: lim sw. Mol Clin Oncol. 2014 Jul;2(4):596-598. doi: 10.3892/mco.2014.274. Epub 2014 Apr 9. Mol Clin Oncol. 2014. PMID: 24940502 Free PMC article.

9

A phase 1 study of ruxolitinib, steroids and lenalidomide for relapsed/refractory multiple myeloma patients.

Berenson JR, Kim C, Bujarski S, To J, Spektor TM, Martinez D, Turner C, Ghermezi M, Eades BM, Swift RA, Schwartz G, Eshaghian S, Moss RA, Lim S, Vescio R. Berenson JR, et al. Hematol Oncol. 2022 Dec;40(5):906-913. doi: 10.1002/hon.3066. Epub 2022 Aug 14. Hematol Oncol. 2022. PMID: 35946431 Clinical Trial.

10

A phase 1/2 study of ixazomib in place of bortezomib or carfilzomib in a subsequent line of therapy for patients with multiple myeloma refractory to their last bortezomib or carfilzomib combination regimen.

Daniely D, Forouzan E, Spektor TM, Cohen A, Bitran JD, Chen G, Moezi MM, Bessudo A, Hrom J, Eshaghian S, Swift RA, Eades BM, Kim C, Lim S, Berenson JR. Daniely D, et al. Exp Hematol. 2022 Jul;111:79-86. doi: 10.1016/j.exphem.2022.04.003. Epub 2022 Apr 10. Exp Hematol. 2022. PMID: 35417741 Free article. Clinical Trial.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

590 results

Search Page

Filters